0|3|Сахар из можжевеловой ягоды [c. 3]0|7|Инструкция по сбору, сушке и хранению можжевеловой ягоды [c. 7]0|8|Инструкция по переработке можжевеловой ягоды на сладкие экстракты и сироп для школ, госпиталей, столовых и домашнего быта  [c. 8]0|11|Использование экстракта и сиропа  [c. 11

Ashley Jones (267526)

Ben Hardwick (3497696)

Farah Barakat (3497699)

Helen Hickey (166297)

Ian Sanderson (3497690)

Mabrouka Altowati (3497693)

Nicolene Plaatjies (3497687)

Paula Williamson (166298)

Richard Russell (385829)

S. Ahmed (569387)

Thomas Jaki (849786)

Pilot and Feasibility Studies

PubMed

Mabrouka A. Altowati

Ashley P. Jones

Helen Hickey

Paula R. Williamson

Farah M. Barakat

Nicolene C. Plaatjies

Ben Hardwick

Richard K. Russell

Thomas Jaki

S. Faisal Ahmed

Ian R. Sanderson

Crossref

Assessing the feasibility of injectable growth-promoting therapy in Crohn’s disease

BackgroundDespite optimal therapy, many children with Crohn's disease (CD) experience growth retardation. The objectives of the study are to assess the feasibility of a randomised control trial (RCT) of injectable forms of growth-promoting therapy and to survey the attitudes of children with CD and their parents to it.MethodsA feasibility study was carried out to determine study arms, sample size and numbers of eligible patients. A face-to-face questionnaire surveyed willingness to consent to future participation in the RCT. Eligibility to the survey was any child under 18 (with their parent/guardian) with CD whose height standard deviation score (HtSDS) was ≤+1. Of 118 questionnaires, 94 (80%) were returned (48 by children and 46 by parents).ResultsThe median age of the patients in the survey was 14.3 years (range 7.0 to 17.7), and 35 (73%) were male. Their median HtSDS was -1.2 (-3.01, 0.23), and it was lower than the median mid-parental HtSDS of -0.6 (-3.1, 1.4). We analysed the willingness of the children whose HtSDS ConclusionsAlmost half of children and parents surveyed would take part in an RCT of growth-promoting therapy. Allaying fears about injections may result in higher recruitment rates

Altowati, Mabrouka A

Jones, Ashley P

Hickey, Helen

Williamson, Paula R

Barakat, Farah M

Plaatjies, Nicolene C

Hardwick, Ben

Russell, Richard K

Jaki, Thomas

Ahmed, S Faisal

Sanderson, Ian R

University of Liverpool Repository

Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease.

Background: Despite optimal therapy, many children with Crohn’s disease (CD) experience growth retardation.

The objectives of the study are to assess the feasibility of a randomised control trial (RCT) of injectable forms of

growth-promoting therapy and to survey the attitudes of children with CD and their parents to it.

Methods: A feasibility study was carried out to determine study arms, sample size and numbers of eligible patients.

A face-to-face questionnaire surveyed willingness to consent to future participation in the RCT. Eligibility to the

survey was any child under 18 (with their parent/guardian) with CD whose height standard deviation score (HtSDS)

was ≤+1. Of 118 questionnaires, 94 (80%) were returned (48 by children and 46 by parents).

Results: The median age of the patients in the survey was 14.3 years (range 7.0 to 17.7), and 35 (73%) were male.

Their median HtSDS was −1.2 (−3.01, 0.23), and it was lower than the median mid-parental HtSDS of −0.6 (−3.1, 1.4).

We analysed the willingness of the children whose HtSDS &lt;−1 to take part in the proposed RCT, being those most

likely to require treatment. Overall, 18 (47%) children and 17 (46%) parents were willing. This increased to 61% of

children who were slightly concerned about their height and 100% (4/4) of those very concerned. A common

reason for not taking part in the RCT was fear of injections (44%); 111 children are required for randomisation into

three study arms from nine centres.

Conclusions: Almost half of children and parents surveyed would take part in an RCT of growth-promoting

therapy. Allaying fears about injections may result in higher recruitment rates

Altowati, Mabrouka A.

Jones, Ashley P.

Williamson, Paula R.

Barakat, Farah M.

Plaatjies, Nicolene C.

Russell, Richard K.

Ahmed, S. Faisal

Sanderson, Ian R.

Enlighten: Publications

Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease

Красинский, Н. П.

Electronic Library Belinsky

Сахар из можжевеловой ягоды: [брошюра]

Young person’s questionnaire. (DOC 59 kb

FigShare

Additional file 1: of Assessing the feasibility of injectable growth-promoting therapy in Crohn’s disease

Enlighten

English

Additional file 2: of Assessing the feasibility of injectable growth-promoting therapy in Crohn’s disease

BACKGROUND: Despite optimal therapy, many children with Crohn's disease (CD) experience growth retardation. The objectives of the study are to assess the feasibility of a randomised control trial (RCT) of injectable forms of growth-promoting therapy and to survey the attitudes of children with CD and their parents to it. METHODS: A feasibility study was carried out to determine study arms, sample size and numbers of eligible patients. A face-to-face questionnaire surveyed willingness to consent to future participation in the RCT. Eligibility to the survey was any child under 18 (with their parent/guardian) with CD whose height standard deviation score (HtSDS) was ≤+1. Of 118 questionnaires, 94 (80%) were returned (48 by children and 46 by parents). RESULTS: The median age of the patients in the survey was 14.3 years (range 7.0 to 17.7), and 35 (73%) were male. Their median HtSDS was -1.2 (-3.01, 0.23), and it was lower than the median mid-parental HtSDS of -0.6 (-3.1, 1.4). We analysed the willingness of the children whose HtSDS <-1 to take part in the proposed RCT, being those most likely to require treatment. Overall, 18 (47%) children and 17 (46%) parents were willing. This increased to 61% of children who were slightly concerned about their height and 100% (4/4) of those very concerned. A common reason for not taking part in the RCT was fear of injections (44%); 111 children are required for randomisation into three study arms from nine centres. CONCLUSIONS: Almost half of children and parents surveyed would take part in an RCT of growth-promoting therapy. Allaying fears about injections may result in higher recruitment rates.This study was supported by funding from Crohn’s in Childhood Research
Association (CICRA). MA is funded by the Higher Education Ministry of
Libyan Government for a postgraduate studentship. RR is supported by a
NHS Research Scotland career fellowship award and has received support
from a Medical Research Council (MRC) patient research cohort initiative
grant (G0800675) for PICTS. The work of the IBD team at the Royal Hospital
for Sick Children is supported by the Catherine McEwan Foundation and the
Yorkhill IBD fun

Altowati, MA

Jones, AP

Hickey, H

Williamson, PR

Barakat, FM

Plaatjies, NC

Hardwick, B

Russell, RK

Jaki, T

Ahmed, SF

Sanderson, IR

Queen Mary Research Online

https://figshare.com/articles/Additional_file_2_of_Assessing_the_feasibility_of_injectable_growth-promoting_therapy_in_Crohn_s_disease/4394414

Сахар из можжевеловой ягоды: [брошюра]

Abstract

Similar works

Full text

Available Versions

Crossref

University of Liverpool Repository

Enlighten: Publications

Electronic Library Belinsky

FigShare

Enlighten

FigShare

Queen Mary Research Online